MYDA Advisors LLC Purchases Shares of 100,000 Alpha Cognition, Inc. (NASDAQ:ACOG)

MYDA Advisors LLC purchased a new position in shares of Alpha Cognition, Inc. (NASDAQ:ACOG - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 100,000 shares of the company's stock, valued at approximately $589,000. MYDA Advisors LLC owned 0.62% of Alpha Cognition as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Altium Capital Management LLC acquired a new stake in shares of Alpha Cognition during the 4th quarter valued at $1,620,000. Rosalind Advisors Inc. purchased a new stake in shares of Alpha Cognition during the fourth quarter worth $1,489,000. ADAR1 Capital Management LLC acquired a new stake in Alpha Cognition during the fourth quarter valued at $1,204,000. Aristides Capital LLC purchased a new position in Alpha Cognition in the fourth quarter valued at about $1,178,000. Finally, National Bank of Canada FI acquired a new stake in shares of Alpha Cognition during the 4th quarter valued at about $69,000.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ACOG. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Alpha Cognition in a research note on Monday, March 31st. Raymond James raised Alpha Cognition to a "moderate buy" rating in a report on Tuesday, March 25th.

Alpha Cognition Stock Up 2.8 %

Shares of NASDAQ ACOG traded up $0.14 during trading hours on Thursday, hitting $5.06. 24,686 shares of the stock were exchanged, compared to its average volume of 79,873. Alpha Cognition, Inc. has a one year low of $3.75 and a one year high of $7.00. The business's 50 day moving average is $5.22. The stock has a market cap of $81.06 million, a price-to-earnings ratio of -1.98 and a beta of 2.50.

Alpha Cognition (NASDAQ:ACOG - Get Free Report) last released its quarterly earnings results on Monday, March 31st. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.03).

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.